United States Patent 8,399,015: Lopinavir/Ritonavir Solid-Dispersion Claims, Patent Scope and Competitive Landscape

U.S. Patent No. 8,399,015 protects solid pharmaceutical dosage forms containing ritonavir, alone or with lopinavir, in a solid dispersion with a high-glass-transition-temperature water-soluble polymer and a moderately lipophilic surfactant. The core technical combination is a polymer with a glass-transition temperature of at least 50°C and a surfactant with an HLB value of 4 to 10.

The claims are formulation claims, not claims to lopinavir, ritonavir, HIV treatment generally, or the manufacturing process itself. The broadest practical risk is directed to a dosage form containing ritonavir in a solid solution or glassy solution using copovidone or a comparable polymer and a sorbitan fatty acid ester or another surfactant within the claimed HLB range.

Based on the patent’s 2013 issuance and its underlying pre-2013 filing history, the patent’s statutory term appears to have ended in 2022. The patent therefore presents historical formulation coverage rather than a current blocking right, subject to confirmation of the official patent-term record. (U.S. Patent No. 8,399,015, 2013; USPTO, n.d.-a)

What does U.S. Patent 8,399,015 protect?

The patent protects a solid dosage form that contains a solid dispersion meeting specified composition and, in narrower claims, performance requirements.

Claim group	Required active ingredient	Required polymer	Required surfactant	Additional limitations
Claims 1-17	Lopinavir and ritonavir	Water-soluble polymer, Tg at least 50°C	HLB 4-10	Some claims require copovidone, sorbitan ester, stability or pharmacokinetic results
Claims 18-27	Ritonavir, with claims 21-27 narrowing to specific combinations	Water-soluble polymer, Tg at least 50°C	HLB 4-10	Claims 22 and 27 specify copovidone and sorbitan monolaurate
Claims 28-31	Ritonavir	One or more water-soluble polymers, Tg at least 50°C	One or more surfactants, HLB 4-10	Solid solution or glassy solution and specified weight ranges

The independent claims are claims 1, 12, 18 and 28. Claims 1 and 12 cover lopinavir/ritonavir products. Claims 18 and 28 cover ritonavir products without requiring lopinavir.

How broad are the independent claims?

Claim 1: lopinavir/ritonavir combination

Claim 1 requires all of the following:

A solid pharmaceutical dosage form.
A solid dispersion.
Lopinavir and ritonavir.
A pharmaceutically acceptable water-soluble polymer with a Tg of at least 50°C.
A pharmaceutically acceptable surfactant with an HLB value from 4 to 10.

The claim does not require a specific polymer, surfactant, manufacturing process, tablet shape, dose, or release profile. A formulation may therefore fall within claim 1 even if it uses a different excipient from the examples, provided the polymer and surfactant satisfy the functional and numerical limitations.

The claim is narrower than a general claim to any solid dispersion of lopinavir and ritonavir. A product using a polymer with a Tg below 50°C, or no surfactant, would fall outside the literal scope of claim 1. A formulation using a surfactant with an HLB below 4 or above 10 would also fall outside the express limitation.

Claim 12: alternative drafting of the combination claim

Claim 12 covers the same general lopinavir/ritonavir concept but expressly permits combinations of polymers and combinations of surfactants. This language expands the coverage beyond a single polymer and a single surfactant.

A competitor cannot necessarily avoid claim 12 by blending two qualifying polymers or two qualifying surfactants. The claim expressly covers those combinations when the required Tg and HLB conditions remain satisfied.

Claim 18: ritonavir-only solid dispersion

Claim 18 is commercially important because it removes lopinavir as a required component. It covers a ritonavir solid dispersion containing:

A water-soluble polymer with Tg of at least 50°C; and
A surfactant with HLB of 4 to 10.

This claim can reach ritonavir-only formulations even when they are not Kaletra-type combination products.

Claim 28: ritonavir-only formulation with combinations

Claim 28 expressly covers combinations of qualifying polymers and combinations of qualifying surfactants. It is the broadest claim group for a ritonavir-only product using multiple excipients within the claimed ranges.

What formulations are specifically protected?

The most commercially relevant embodiments are copovidone-based solid dispersions containing a sorbitan fatty acid ester.

Copovidone

Claims 3, 4, 5, 21, 22, 26 and 27 identify copovidone or a copolymer of N-vinylpyrrolidone and vinyl acetate. Copovidone is a water-soluble polymer commonly used to stabilize amorphous pharmaceutical dispersions.

The claims do not require a single grade of copovidone. A product analysis would need to determine whether the selected material is within the claimed polymer class and whether its Tg meets the threshold.

Sorbitan fatty acid esters

Claims 2, 5, 20, 21 and 26 cover sorbitan fatty acid esters. Claim 22 and claim 27 narrow the surfactant to sorbitan monolaurate.

The HLB requirement is central. A sorbitan ester outside the 4-to-10 HLB range may avoid the literal limitation, depending on the product’s actual material specification and the method used to assign HLB.

Solid solution or glassy solution

Claims 6, 7, 15, 19 and 29 require or recite a solid solution or glassy solution. These terms distinguish the claimed dosage forms from a simple physical blend in which crystalline active pharmaceutical ingredient remains dispersed among excipients.

A product assessment would normally examine powder X-ray diffraction, differential scanning calorimetry, microscopy, spectroscopy and dissolution behavior. The key question is whether lopinavir or ritonavir is molecularly dispersed or present in an amorphous glassy phase rather than as a separate crystalline phase.

How do the dependent claims narrow infringement risk?

The dependent claims add four principal limitations.

Limitation	Claims	Practical effect
Copovidone or N-vinylpyrrolidone/vinyl acetate copolymer	3-5, 21, 22, 26, 27	Narrows the polymer identity
Sorbitan fatty acid ester	2, 5, 20, 21, 26	Narrows the surfactant class
Solid solution or glassy solution	6, 7, 15, 19, 29	Narrows the physical state
Polymer and surfactant weight ranges	11, 25, 31	Requires 50-85% polymer and 2-20% surfactant

The weight-range claims are significant because they require the polymer and surfactant percentages to be measured against the total dosage form. A product can avoid those dependent claims while still implicating an independent claim if its formulation satisfies the broader solid-dispersion limitations.

What performance limitations appear in the patent?

Claims 9, 16 and 23 require pharmacokinetic performance in dogs under non-fasting conditions. The thresholds are:

Ritonavir AUC of at least 9 µg·h/mL per 100 mg; and
Lopinavir AUC of at least 20 µg·h/mL per 100 mg for the combination claims.

Claims 10, 17 and 24 require retention of at least 98% of the initial ritonavir content after six weeks at 40°C and 75% relative humidity.

These limitations may create evidentiary issues in litigation. A patentee would need to establish that the accused dosage form satisfies the specified performance characteristic. A generic applicant may challenge whether the claim limitation is met across the commercial batch, rather than only in a selected laboratory formulation.

Does the patent cover Kaletra?

The claim structure is directed at the same active-ingredient combination used in Kaletra, but the patent does not automatically cover every lopinavir/ritonavir product.

Kaletra products would need to be evaluated against the following elements:

Whether lopinavir and ritonavir are present in a solid dispersion.
Whether the polymer has a Tg of at least 50°C.
Whether the surfactant has an HLB of 4 to 10.
Whether the dispersion is a solid or glassy solution for the narrower claims.
Whether the specified polymer and surfactant weight ranges apply.

The FDA-approved Kaletra label identifies lopinavir and ritonavir as active ingredients and describes tablet and oral-solution dosage forms. The label alone does not establish infringement of the asserted formulation claims. Product composition, excipient identity and solid-state characterization are required. (FDA, 2024a)

What is the Orange Book status of U.S. Patent 8,399,015?

U.S. Patent 8,399,015 should be distinguished from patents listed in the FDA Orange Book for Kaletra or ritonavir products.

The Orange Book lists patents submitted by NDA holders for approved drug products. A patent may be relevant to a formulation without being listed in the Orange Book. Conversely, an Orange Book-listed patent may cover a different aspect of the product, such as the active compound, dosing regimen, formulation, method of use or crystalline form.

The relevant Orange Book questions are:

Whether Patent 8,399,015 was submitted for the Kaletra NDA.
Whether it was listed for tablets, oral solution or another dosage form.
Whether the listing remained active before statutory expiration.
Whether an ANDA applicant was required to make a Paragraph IV certification against it.

Current FDA Orange Book records should control the listing determination. The patent’s formulation scope cannot be inferred solely from its presence or absence in a commercial label. (FDA, 2024b)

When did U.S. Patent 8,399,015 lose exclusivity?

Patent 8,399,015 appears to have reached the end of its ordinary 20-year patent term in 2022, based on its pre-2013 priority and filing history. The patent issued on March 19, 2013. Patent term adjustment, terminal disclaimers and the earliest effective nonprovisional filing date control the final expiration date. (U.S. Patent No. 8,399,015, 2013; USPTO, n.d.-b)

The patent’s expiration means that:

No current U.S. injunction should issue solely from this patent if it has expired.
A Paragraph IV challenge against this patent would have had greater commercial relevance before expiration.
A generic or follow-on manufacturer can no longer be blocked by this patent alone after expiration.
Other patents, regulatory exclusivities, trade secrets or manufacturing barriers may still affect market entry.

FDA regulatory exclusivity is separate from patent exclusivity. New-drug, pediatric and orphan exclusivities, where applicable, do not extend the patent term. (FDA, 2024c)

Were Paragraph IV challenges likely relevant?

A Paragraph IV certification is relevant only when an ANDA applicant references an NDA and identifies an Orange Book-listed patent as invalid, unenforceable or not infringed.

For a lopinavir/ritonavir generic, the principal technical attack points against this patent would have included:

Whether the formulation contains a qualifying solid dispersion.
Whether the polymer Tg meets the 50°C threshold.
Whether the surfactant HLB value falls within 4 to 10.
Whether the active ingredient is present as a solid solution or glassy solution.
Whether the formulation satisfies the AUC or stability limitations.
Whether the claims were anticipated or rendered obvious by prior solid-dispersion work.

The patent’s functional limitations create both infringement and validity issues. HLB and Tg are measurable parameters, but their application can depend on material grade, test method, temperature and composition.

Which companies challenged lopinavir/ritonavir exclusivity?

The principal commercial product was developed and marketed by Abbott Laboratories, later associated with AbbVie, under the Kaletra brand. Ritonavir was also marketed under Norvir.

Publicly visible generic activity for lopinavir/ritonavir has been limited compared with major small-molecule products. The principal reasons include the specialized formulation requirements, the relatively narrow commercial market, prior patent coverage and the technical difficulty of reproducing exposure from an amorphous or solid-dispersion formulation.

A complete company-by-company Paragraph IV table cannot be established from the claim text alone. FDA ANDA records and district-court dockets are required to attribute individual challenges, settlements and launch dates. The patent itself does not identify the challenger landscape.

How strong is the patent estate?

Strengths

The patent has several features that made it meaningful before expiration:

It covers both lopinavir/ritonavir and ritonavir-only formulations.
It reaches broad classes of polymers and surfactants.
It expressly covers combinations of polymers and surfactants.
It includes composition, solid-state, stability and pharmacokinetic limitations.
It targets a formulation problem associated with poorly water-soluble protease inhibitors.

Weaknesses

The patent also has material limitations:

It requires a solid dosage form and does not cover liquid formulations.
It requires a solid dispersion.
The polymer must meet a quantitative Tg threshold.
The surfactant must meet a quantitative HLB range.
Several dependent claims require a specific physical state or analytical outcome.
The patent is no longer a current U.S. exclusivity barrier if its 2022 expiration is confirmed.

The claims are stronger against a close copy using copovidone and a sorbitan ester than against a product using a different polymer system, a different surfactant range or a crystalline formulation.

What manufacturing and IP barriers remain?

Even after patent expiration, a generic manufacturer may face non-patent barriers:

Reproducing the amorphous solid dispersion at commercial scale.
Preventing recrystallization during storage.
Achieving consistent dissolution and bioavailability.
Controlling residual solvent and moisture.
Demonstrating bioequivalence for a formulation with nonlinear pharmacokinetic behavior.
Establishing process control for spray drying, melt processing or solvent evaporation.
Protecting manufacturing know-how through trade secrets.

These barriers do not extend the patent term. They can, however, delay development and increase the cost of a generic launch.

How does this patent compare with other lopinavir/ritonavir protection?

Protection category	Typical subject matter	Relevance to Patent 8,399,015
Active-ingredient patents	Lopinavir, ritonavir or related compounds	Separate from this formulation patent
Combination patents	Lopinavir plus ritonavir	Overlap with claims 1-17
Solid-dispersion patents	Amorphous or glassy drug-polymer systems	Directly relevant
Dosage patents	Strength, ratio, tablet or liquid dosage form	Potentially overlapping but distinct
Method-of-use patents	HIV treatment or dosing regimens	Not claimed here
Process patents	Spray drying, granulation or manufacturing steps	Not claimed here
Regulatory exclusivity	FDA approval-based exclusivity	Separate from patent rights

Patent 8,399,015 is therefore best classified as a formulation patent with solid-state and excipient limitations. It is not a method-of-use patent and does not claim the underlying protease-inhibitor chemistry.

What is the generic launch risk?

Before expiration, a generic closely matching the patent’s formulation would have faced meaningful Paragraph IV and infringement risk. The highest-risk profile would have been:

Lopinavir plus ritonavir.
Copovidone or a comparable high-Tg polymer.
Sorbitan monolaurate or another sorbitan fatty acid ester.
A solid or glassy solution.
Polymer content of 50-85%.
Surfactant content of 2-20%.

A lower-risk design-around would use a different solid-state strategy, a polymer below the claimed Tg threshold, a surfactant outside the HLB range or a non-solid dosage form. Such changes would still require bioequivalence and stability validation.

After patent expiration, the risk shifts from infringement to regulatory, technical and commercial execution. Remaining risk would arise from other unexpired patents, Orange Book listings, formulation equivalence requirements and manufacturing scale-up.

Key Takeaways

U.S. Patent 8,399,015 covers solid dispersions of ritonavir alone or with lopinavir.
The core limitations are a water-soluble polymer with Tg of at least 50°C and a surfactant with HLB of 4 to 10.
Copovidone and sorbitan fatty acid esters are the most specifically identified formulation components.
Claims 1-17 focus on lopinavir/ritonavir; claims 18-31 extend coverage to ritonavir-only products.
Claims 9, 16 and 23 add dog AUC thresholds; claims 10, 17 and 24 add accelerated stability requirements.
Claims 11, 25 and 31 require 50-85% polymer and 2-20% surfactant by total dosage-form weight.
The patent is a formulation patent, not a method-of-use or active-compound patent.
Its ordinary U.S. patent term appears to have ended in 2022.
The historical infringement risk was highest for copovidone/sorbitan-ester solid dispersions.
Current market risk depends primarily on other patents, Orange Book status, FDA requirements and manufacturing capability.

FAQs

Does Patent 8,399,015 cover ritonavir oral solution?

No. The claims require a solid pharmaceutical dosage form. A liquid oral solution is outside the literal dosage-form limitation, although other patents or regulatory protections may apply.

Can a formulation avoid the patent by using a different surfactant?

Potentially. The surfactant must have an HLB value from 4 to 10. A formulation using a surfactant outside that range may avoid the literal surfactant limitation, subject to analysis of all claim elements and equivalents.

Does the patent require copovidone?

No. The independent claims cover a broader class of pharmaceutically acceptable water-soluble polymers with a Tg of at least 50°C. Copovidone is required only in selected dependent claims.

Are the AUC limitations required for every claim?

No. The AUC thresholds appear only in claims 9, 16 and 23. The independent claims do not uniformly require the dog pharmacokinetic results.

Does patent expiration eliminate FDA bioequivalence requirements?

No. Patent expiration removes the patent barrier but does not remove the need for an approved ANDA, NDA supplement or other applicable FDA pathway, including product-specific bioequivalence and quality requirements.

References

Abbott Laboratories. (2013). Pharmaceutical compositions comprising protease inhibitors, U.S. Patent No. 8,399,015. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024a). Kaletra (lopinavir/ritonavir) prescribing information. FDA.
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024c). Small business and industry assistance: Exclusivity and patent listings. FDA.
United States Patent and Trademark Office. (n.d.-a). Patent examination data system and patent full-text records. USPTO.
United States Patent and Trademark Office. (n.d.-b). Patent term adjustment and patent term calculation resources. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055734	⤷ Start Trial
Argentina	077411	⤷ Start Trial
Australia	2006216856	⤷ Start Trial
Brazil	122012031169	⤷ Start Trial
Brazil	PI0609173	⤷ Start Trial
Canada	2598827	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,399,015

Summary for Patent: 8,399,015